JP2018521641A5 - - Google Patents

Download PDF

Info

Publication number
JP2018521641A5
JP2018521641A5 JP2017563564A JP2017563564A JP2018521641A5 JP 2018521641 A5 JP2018521641 A5 JP 2018521641A5 JP 2017563564 A JP2017563564 A JP 2017563564A JP 2017563564 A JP2017563564 A JP 2017563564A JP 2018521641 A5 JP2018521641 A5 JP 2018521641A5
Authority
JP
Japan
Prior art keywords
seq
peptide
cancer
cell
variant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017563564A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018521641A (ja
Filing date
Publication date
Priority claimed from GBGB1511546.2A external-priority patent/GB201511546D0/en
Application filed filed Critical
Publication of JP2018521641A publication Critical patent/JP2018521641A/ja
Publication of JP2018521641A5 publication Critical patent/JP2018521641A5/ja
Priority to JP2021092252A priority Critical patent/JP7404306B2/ja
Priority to JP2023209805A priority patent/JP2024037858A/ja
Pending legal-status Critical Current

Links

JP2017563564A 2015-07-01 2016-06-29 卵巣がんおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ Pending JP2018521641A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2021092252A JP7404306B2 (ja) 2015-07-01 2021-06-01 卵巣がんおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ
JP2023209805A JP2024037858A (ja) 2015-07-01 2023-12-13 卵巣がんおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562187507P 2015-07-01 2015-07-01
GBGB1511546.2A GB201511546D0 (en) 2015-07-01 2015-07-01 Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
US62/187,507 2015-07-01
GB1511546.2 2015-07-01
PCT/EP2016/065166 WO2017001491A2 (en) 2015-07-01 2016-06-29 Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021092252A Division JP7404306B2 (ja) 2015-07-01 2021-06-01 卵巣がんおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ

Publications (2)

Publication Number Publication Date
JP2018521641A JP2018521641A (ja) 2018-08-09
JP2018521641A5 true JP2018521641A5 (https=) 2019-06-13

Family

ID=53872514

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017563564A Pending JP2018521641A (ja) 2015-07-01 2016-06-29 卵巣がんおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ
JP2021092252A Active JP7404306B2 (ja) 2015-07-01 2021-06-01 卵巣がんおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021092252A Active JP7404306B2 (ja) 2015-07-01 2021-06-01 卵巣がんおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ

Country Status (24)

Country Link
US (19) US20170037111A1 (https=)
EP (2) EP3317296B1 (https=)
JP (2) JP2018521641A (https=)
KR (1) KR20180022968A (https=)
CN (1) CN113480604A (https=)
AU (2) AU2016286274B2 (https=)
BR (1) BR112017027459A2 (https=)
CA (1) CA2990989A1 (https=)
CR (1) CR20180001A (https=)
DK (1) DK3317296T3 (https=)
EA (2) EA201992664A3 (https=)
ES (1) ES2839223T3 (https=)
GB (1) GB201511546D0 (https=)
HU (1) HUE052820T2 (https=)
LT (1) LT3317296T (https=)
MA (2) MA41520B2 (https=)
MD (1) MD3317296T2 (https=)
MX (1) MX2017017145A (https=)
PT (1) PT3317296T (https=)
RS (1) RS61190B1 (https=)
SG (1) SG10202001665QA (https=)
SI (1) SI3317296T1 (https=)
UA (1) UA123699C2 (https=)
WO (1) WO2017001491A2 (https=)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010033941A1 (en) 2008-09-22 2010-03-25 Array Biopharma Inc. Substituted imidazo[1,2b]pyridazine compounds as trk kinase inhibitors
MY169791A (en) 2008-10-22 2019-05-15 Array Biopharma Inc Substituted pyrazolo [1,5-a] pyrimidine compounds as trk kinase inhibitors
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
ME03376B (me) 2010-05-20 2020-01-20 Array Biopharma Inc Makrociklička jedinjenja kао inhibiтori trk kinaze
CN113354649B (zh) 2014-11-16 2024-12-10 阵列生物制药公司 一种新的晶型
GB201511546D0 (en) 2015-07-01 2015-08-12 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
MA54884A (fr) 2015-07-01 2022-01-12 Immatics Biotechnologies Gmbh Neuartige peptide und kombination aus peptiden zur verwendung in der immuntherapie gegen ovarialkarzinom und andere karzinome
US10716544B2 (en) 2015-10-08 2020-07-21 Zmk Medical Technologies Inc. System for 3D multi-parametric ultrasound imaging
EP3368039A1 (en) 2015-10-26 2018-09-05 The Regents of The University of Colorado, A Body Corporate Point mutations in trk inhibitor-resistant cancer and methods relating to the same
GB201520563D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201521746D0 (en) * 2015-12-10 2016-01-27 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against CLL and other cancers
ES2970865T3 (es) 2015-12-16 2024-05-31 Gritstone Bio Inc Identificación, fabricación y uso de neoantígenos
GB201602918D0 (en) * 2016-02-19 2016-04-06 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against NHL and other cancers
GB201604490D0 (en) 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Peptides combination of peptides for use in immunotherapy against cancers
FI3439662T3 (fi) 2016-04-04 2024-09-04 Loxo Oncology Inc (s)-n-(5-((r)-2-(2,5-difluorifenyyli)pyrrolidin-1-yyli)pyratsolo[1,5-a]pyrimidin-3-yyli)-3-hydroksipyrrolidiini-1-karboksamidin nesteformulaatioita
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
US11261223B2 (en) 2016-05-11 2022-03-01 The University Of Chicago Methods of treating cancers with CT45 targeted therapies
EP3458456B1 (en) 2016-05-18 2020-11-25 Loxo Oncology Inc. Preparation of (s)-n-(5-((r)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide
JP7075125B2 (ja) 2016-05-25 2022-05-25 イマティクス バイオテクノロジーズ ゲーエムベーハー 標的としてのおよび胆嚢がんおよび胆管がんおよびその他のがんに対する免疫療法で使用するための新規ペプチド、ペプチド組み合わせ
GB201609193D0 (en) 2016-05-25 2016-07-06 Immatics Biotechnologies Gmbh Novel peptides, combination of peptides as targets for use in immunotherapy against gallbladder cancer and cholangiocarcinoma and other cancers
CN109843327B (zh) 2016-07-07 2022-05-13 小利兰·斯坦福大学托管委员会 抗体佐剂缀合物
JOP20190092A1 (ar) 2016-10-26 2019-04-25 Array Biopharma Inc عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
CN110167956B (zh) * 2016-11-30 2023-04-07 深圳华大生命科学研究院 多肽及其应用
KR102379955B1 (ko) 2016-12-08 2022-03-29 이매틱스 바이오테크놀로지스 게엠베하 짝짓기가 향상된 t 세포 수용체
DE102016123893A1 (de) 2016-12-08 2018-06-14 Immatics Biotechnologies Gmbh T-Zellrezeptoren mit verbesserter Bindung
CN106636107B (zh) * 2017-01-20 2018-07-31 江苏集萃药康生物科技有限公司 一种喉癌细胞的核酸适配体及试剂盒
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
BR112019020959A2 (pt) * 2017-04-10 2020-05-05 Immatics Biotechnologies Gmbh peptídeos e combinações dos mesmos para uso na imunoterapia contra câncer
KR101970709B1 (ko) * 2017-06-13 2019-04-22 가톨릭대학교 산학협력단 PLK1 단백질에 대한 항원―특이 T 세포 면역반응을 유도하는 HLA―A2 아형―특이 PLKl―유래 항원결정기
DE102017115966A1 (de) 2017-07-14 2019-01-17 Immatics Biotechnologies Gmbh Polypeptidmolekül mit verbesserter zweifacher Spezifität
LT3428194T (lt) 2017-07-14 2021-12-10 Immatics Biotechnologies Gmbh Pagerinta dvejopo savitumo polipeptido molekulė
AU2018311130A1 (en) * 2017-08-02 2020-02-20 Idp Discovery Pharma, S.L. Anticancer peptides
CA3076918A1 (en) * 2017-10-02 2019-04-11 Curematch, Inc. Method of prediction of tumor-derived neo-peptide antigenicity and/or immunogenicity using mutational signature patterns
EP4576103A3 (en) 2017-10-10 2025-08-27 Gritstone bio, Inc. Neoantigen identification using hotspots
CN111630602A (zh) 2017-11-22 2020-09-04 磨石肿瘤生物技术公司 减少新抗原的接合表位呈递
DE102017127984B4 (de) 2017-11-27 2019-12-05 Immatics US, Inc. Verfahren für die Vermehrung und Aktivierung von γδ-T-Zellen
WO2019112489A1 (en) * 2017-12-05 2019-06-13 Limited Liability Company "Gero" Methods and agents for treatment of aging and aging related conditions and diseases
EP3746087A4 (en) * 2018-01-31 2022-02-09 Nx Prenatal Inc. METHODS FOR EARLY DETECTION AND PREVENTION OF PREECLAMPIA USING CIRCULATION MICROPARTICLE-ASSOCIATED BIOMARKERS
BR112020016176A2 (pt) 2018-02-09 2022-02-22 Immatics Us Inc Métodos de transdução de uma célula t, célula t transduzida geneticamente, composição farmacêutica, métodos de preparação de uma população de células t e uso da célula t
AU2019218397A1 (en) 2018-02-12 2020-10-01 Fred Hutchinson Cancer Center Cyclin A1 specific T cell receptors and uses thereof
DE102018108612A1 (de) 2018-03-21 2019-09-26 Immatics US, Inc. Verfahren zur erhöhung der persistenz von adoptiv infundierten t-zellen
TW202016131A (zh) * 2018-05-16 2020-05-01 德商英麥提克生物技術股份有限公司 用於抗癌免疫治療的肽
CN108939090B (zh) * 2018-07-13 2021-01-01 厦门大学 一种脂质体、制备方法及用途
TW202019955A (zh) * 2018-07-31 2020-06-01 德商英麥提克生物技術股份有限公司 B*07 限制肽和肽組合的抗癌免疫治療和相關方法
TWI852977B (zh) 2019-01-10 2024-08-21 美商健生生物科技公司 前列腺新抗原及其用途
WO2020190725A1 (en) 2019-03-15 2020-09-24 Bolt Biotherapeutics, Inc. Immunoconjugates targeting her2
US20200297768A1 (en) 2019-03-19 2020-09-24 Immatics US, Inc. Cd28 t cell cultures, compositions, and methods of using thereof
WO2020243134A1 (en) 2019-05-27 2020-12-03 Immatics US, Inc. Viral vectors and their use in adoptive cellular therapy
US12011459B2 (en) 2019-06-06 2024-06-18 Immatics US, Inc. Methods for manufacturing T cells by direct sorting and compositions thereof
WO2020252145A1 (en) * 2019-06-11 2020-12-17 Iogenetics, Llc Neoantigen immunotherapies
US20210032370A1 (en) 2019-08-02 2021-02-04 Immatics Biotechnologies Gmbh Recruiting agent further binding an mhc molecule
CN112409449B (zh) * 2019-08-19 2023-12-15 辽宁中健医药科技有限公司 Hla-a0201限定性kif15特异性抗肿瘤ctl优势表位肽及应用
JP7711045B2 (ja) 2019-09-02 2025-07-22 アンスティテュ・クリー 腫瘍ネオアンチゲンペプチドを標的とする免疫療法
CN110596386B (zh) * 2019-09-20 2020-06-02 四川大学华西医院 Egflam自身抗体检测试剂在制备肺癌筛查试剂盒中的用途
CA3168729A1 (en) 2020-02-24 2021-09-02 Melinda MATA Methods for expanding t cells for the treatment of cancer and related malignancies
DE102020106710A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
DE102020111571A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
EP4127243B1 (en) * 2020-03-23 2023-11-22 Koninklijke Philips N.V. Prediction of radiotherapy response for prostate cancer subject based on immune checkpoint genes
CA3173666A1 (en) * 2020-04-14 2021-10-21 Claude Perreault Novel tumor-specific antigens for acute myeloid leukemia (aml) and uses thereof
EP4175664A2 (en) 2020-07-06 2023-05-10 Janssen Biotech, Inc. Prostate neoantigens and their uses
AU2021305652A1 (en) * 2020-07-08 2023-02-23 Mercy Bioanalytics, Inc. Compositions and methods for detection of lung cancer
US20220056411A1 (en) 2020-08-21 2022-02-24 Immatics US, Inc. Methods for isolating cd8+ selected t cells
CN112691192B (zh) * 2020-12-01 2022-09-20 上海交通大学医学院附属新华医院 GOLM1在制备负性调控cell-in-cell结构的形成的药物中的应用
EP4255465A4 (en) * 2020-12-07 2025-02-26 Iogenetics, LLC. Bystander protein vaccines
TW202241938A (zh) 2020-12-31 2022-11-01 美商英麥提克斯股份有限公司 Cd8多肽、組合物及其使用方法
IL308258A (en) 2021-05-05 2024-01-01 Immatics Biotechnologies Gmbh Bma031 antigen binding polypeptides
CN113350507B (zh) * 2021-07-19 2022-04-15 南通大学 Cep55作为靶点在制备诊断、预防或治疗结肠炎的药物中的应用
JP2024534825A (ja) 2021-08-24 2024-09-26 イマティクス ユーエス,アイエヌシー. 条件付きリガンド交換により産生されたペプチドmhc複合体を使用する免疫細胞の選択
TW202332765A (zh) 2021-09-20 2023-08-16 美商英麥提克斯股份有限公司 用於t細胞療法之t細胞群體的單核球耗盡
WO2023056240A2 (en) 2021-09-28 2023-04-06 Frontaim Biomedicines, Inc. Multiple formats of molecular complexes
EP4448108A1 (en) 2021-11-08 2024-10-23 Immatics Biotechnologies GmbH Adoptive cell therapy combination treatment and compositions thereof
CN114395625B (zh) * 2021-12-29 2023-08-04 广东省人民医院 Copa在制备子宫颈癌诊断生物标记物和/或子宫颈癌药物开发中的应用
EP4514821A1 (en) 2022-04-28 2025-03-05 Immatics US, Inc. Il-12 polypeptides, il-15 polypeptides, il-18 polypeptides, cd8 polypeptides, compositions, and methods of using thereof
EP4514829A1 (en) 2022-04-28 2025-03-05 Immatics US, Inc. Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof
US20230348561A1 (en) 2022-04-28 2023-11-02 Immatics US, Inc. Dominant negative tgfbeta receptor polypeptides, cd8 polypeptides, cells, compositions, and methods of using thereof
CN114592006A (zh) * 2022-04-29 2022-06-07 昆明理工大学 Memo1基因的新用途
WO2023215825A1 (en) 2022-05-05 2023-11-09 Immatics US, Inc. Methods for improving t cell efficacy
CN114751961B (zh) * 2022-06-14 2022-09-20 中山大学孙逸仙纪念医院 circ0005199-173aa蛋白及其在制备食管癌诊断产品中的应用
KR102921994B1 (ko) * 2022-09-22 2026-02-03 차의과학대학교 산학협력단 파클리탁셀에 대하여 내성을 갖는 난소암의 진단을 위한 분석방법
CN117074541B (zh) * 2022-09-23 2025-11-25 西湖大学 预测卵巢癌病人辅助化疗敏感性的蛋白标志物及应用
CN116042825B (zh) * 2022-09-28 2025-07-01 南方医科大学 一种评估5-fu治疗胃癌癌敏感性的探针引物组及其试剂盒
CN116064806B (zh) * 2022-10-19 2023-09-22 常州国药医学检验实验室有限公司 一种评估早期胃癌淋巴结转移风险的组合物及其用途
KR20250038870A (ko) * 2023-09-12 2025-03-20 (주) 수파드엘릭사 레티노산 수용체 활성화 펩타이드 및 이를 포함하는 화장료 조성물
WO2025096649A1 (en) 2023-11-01 2025-05-08 Immatics US, Inc. Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof
CN119287020B (zh) * 2024-12-11 2025-03-07 湖南宏雅基因技术有限公司 一种甲状腺癌甲基化水平检测的引物探针组合物及其应用
CN120966999B (zh) * 2025-10-22 2026-01-09 宁波大学 Klhl14基因在制备结肠癌、5-fu耐受结肠癌诊断试剂中的应用

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4440859A (en) 1977-05-27 1984-04-03 The Regents Of The University Of California Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
LU88258I2 (https=) 1978-12-22 1994-02-03
US4530901A (en) 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US4342566A (en) 1980-02-22 1982-08-03 Scripps Clinic & Research Foundation Solid phase anti-C3 assay for detection of immune complexes
US4678751A (en) 1981-09-25 1987-07-07 Genentech, Inc. Hybrid human leukocyte interferons
US4766075A (en) 1982-07-14 1988-08-23 Genentech, Inc. Human tissue plasminogen activator
US4582800A (en) 1982-07-12 1986-04-15 Hoffmann-La Roche Inc. Novel vectors and method for controlling interferon expression
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US4677063A (en) 1985-05-02 1987-06-30 Cetus Corporation Human tumor necrosis factor
US4810648A (en) 1986-01-08 1989-03-07 Rhone Poulenc Agrochimie Haloarylnitrile degrading gene, its use, and cells containing the gene
US4897445A (en) 1986-06-27 1990-01-30 The Administrators Of The Tulane Educational Fund Method for synthesizing a peptide containing a non-peptide bond
ATE183513T1 (de) 1993-06-03 1999-09-15 Therapeutic Antibodies Inc Herstellung von antikörperfragmenten
AUPM322393A0 (en) 1993-12-24 1994-01-27 Austin Research Institute, The Mucin carbohydrate compounds and their use in immunotherapy
CA2243235C (en) 1996-01-17 2010-08-10 Imperial College Innovations Limited Immunotherapy using cytotoxic t lymphocytes (ctl)
US5849589A (en) 1996-03-11 1998-12-15 Duke University Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
TW452771B (en) * 1998-09-18 2001-09-01 Sony Corp Reproduction apparatus and reproduction method
US20020119158A1 (en) 1998-12-17 2002-08-29 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
US6858710B2 (en) * 1998-12-17 2005-02-22 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
WO2001047944A2 (en) 1999-12-28 2001-07-05 Curagen Corporation Nucleic acids containing single nucleotide polymorphisms and methods of use thereof
US20040191260A1 (en) 2003-03-26 2004-09-30 Technion Research & Development Foundation Ltd. Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
IL151860A0 (en) 2000-03-27 2003-04-10 Technion Res & Dev Foundation Single chain class i major histocompatibility complexes, constructs encoding same and methods of generating same
US6436703B1 (en) 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
AU7524601A (en) 2000-06-05 2001-12-17 Sunol Molecular Corp T cell receptor fusions and conjugates and methods of use thereof
WO2003020884A2 (en) * 2001-08-14 2003-03-13 The Government Of The United States Of America As Represented By The Secretary Of Health And Human Services Method for rapid generation of mature dendritic cells
US20040142325A1 (en) * 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
US6992176B2 (en) 2002-02-13 2006-01-31 Technion Research & Development Foundation Ltd. Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
AU2003216341A1 (en) 2002-02-20 2003-09-09 Dyax Corporation Mhc-peptide complex binding ligands
DE10225144A1 (de) 2002-05-29 2003-12-18 Immatics Biotechnologies Gmbh An MHC-Moleküle bindende Tumor-assoziierte Peptide
WO2003104429A2 (en) * 2002-06-10 2003-12-18 Idec Pharmaceuticals Corporation Genes overexpressed by ovarian cancer and their use in developing novel therapeutics
CA2491017A1 (en) 2002-07-03 2004-01-15 Immunogen, Inc. Antibodies to non-shed muc1 and muc16, and uses thereof
CA2501870C (en) 2002-10-09 2013-07-02 Avidex Limited Single chain recombinant t cell receptors
PT1558643E (pt) 2002-11-09 2009-08-24 Immunocore Ltd Apresentação de um receptor das células t
GB0304068D0 (en) 2003-02-22 2003-03-26 Avidex Ltd Substances
US7348007B2 (en) * 2004-02-09 2008-03-25 Ludwig Institute For Cancer Research Mage C2 antigenic peptides and uses thereof
DE102004026135A1 (de) 2004-05-25 2006-01-05 Immatics Biotechnologies Gmbh An MHC-Moleküle bindende Tumor-assoziierte Peptide
US20110177079A1 (en) 2004-09-08 2011-07-21 Ludwig Institute For Cancer Research Cancer-testis antigens
JP4987698B2 (ja) 2005-03-31 2012-07-25 中外製薬株式会社 癌関連抗原アナログペプチド、およびその利用
JP4962687B2 (ja) 2005-08-30 2012-06-27 Nok株式会社 密封構造
SI1806358T1 (sl) 2005-09-05 2010-06-30 Immatics Biotechnologies Gmbh S tumorjem povezani peptidi ki se promiskuitetnovežejo na molekule humanega levkocitnega antigena HLA razreda II
EP1760089B1 (en) 2005-09-05 2009-08-19 Immatics Biotechnologies GmbH Tumor-associated peptides binding to human leukocyte antigen (HLA) class I or II molecules and related anti-cancer vaccine
ES2444695T3 (es) 2006-06-23 2014-02-26 Alethia Biotherapeutics Inc. Polinucleótidos y polipéptidos implicados en el cáncer
US8097242B2 (en) * 2006-10-05 2012-01-17 The Board Of Trustees Of The University Of Arkansas Target CA125 peptides for cancer immunotherapy
EP2155898A2 (en) 2007-04-05 2010-02-24 Source Precision Medicine, Inc. Gene expression profiling for identification, monitoring and treatment of ovarian cancer
CN103864893B (zh) * 2007-07-27 2017-01-04 伊玛提克斯生物技术有限公司 免疫疗法的免疫抗原表位
HRP20150820T1 (xx) 2007-07-27 2015-09-11 Immatics Biotechnologies Gmbh Nova imunoterapija protiv neuronskih tumora i tumora mozga
HUE032379T2 (en) * 2007-07-27 2017-09-28 Immatics Biotechnologies Gmbh Composition of tumour-associated peptides and related anti-cancer vaccine
EP3115469B1 (en) 2007-11-19 2020-04-29 Celera Corporation Lung cancer markers and uses thereof
US20090263574A1 (en) 2008-04-21 2009-10-22 Quinn Daniel E Method of restoring an article
US20100029748A1 (en) 2008-08-04 2010-02-04 Sloan-Kettering Institute For Cancer Research Metastasis Promoting Genes and Proteins
RS53782B1 (sr) 2008-10-01 2015-06-30 Immatics Biotechnologies Gmbh Preparati tumor-asociranih peptida i odgovarajuća antikancerska vakcina za tretman glioblastoma (gbm) i drugih kancera
WO2010088688A2 (en) 2009-02-02 2010-08-05 Biotheranostics, Inc. Diagnosis of in situ and invasive breast cancer
CN102348979A (zh) 2009-03-09 2012-02-08 乔治亚大学研究基金公司 胃癌诊断用蛋白标记的鉴定
GB201004551D0 (en) 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
WO2013040142A2 (en) * 2011-09-16 2013-03-21 Iogenetics, Llc Bioinformatic processes for determination of peptide binding
CA3255551A1 (en) 2010-03-26 2025-04-15 Memorial Sloan-Kettering Cancer Center MUC16 ANTIBODIES AND METHODS OF USE
GB201006360D0 (en) 2010-04-16 2010-06-02 Immatics Biotechnologies Gmbh Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development
EP2569626B1 (en) 2010-05-11 2019-11-27 Veracyte, Inc. Methods and compositions for diagnosing conditions
GB201009222D0 (en) 2010-06-02 2010-07-21 Immatics Biotechnologies Gmbh Improved cancer therapy based on tumour associated antigens derived from cyclin D1
CN102372773B (zh) 2010-08-11 2013-06-05 中国科学院生物物理研究所 人膀胱癌肿瘤标志物及其抗体和应用
EP2632955A1 (en) 2010-10-26 2013-09-04 Technion Research & Development Foundation Ltd. Antibodies which bind soluble t-cell receptor ligands
US10260097B2 (en) 2011-06-02 2019-04-16 Almac Diagnostics Limited Method of using a gene expression profile to determine cancer responsiveness to an anti-angiogenic agent
CN103782174A (zh) 2011-06-07 2014-05-07 卡里斯生命科学卢森堡控股有限责任公司 用于癌症的循环生物标志物
WO2013057586A1 (en) 2011-10-19 2013-04-25 Oslo Universitetssykehus Hf Compositions and methods for producing soluble t - cell receptors
CN104080797A (zh) 2011-11-11 2014-10-01 弗雷德哈钦森癌症研究中心 针对癌症的靶向细胞周期蛋白a1的t细胞免疫疗法
GB201201511D0 (en) * 2012-01-30 2012-03-14 Univ Leuven Kath Modified epitopes for boosting CD4+ T-cell responses
WO2014011465A2 (en) * 2012-07-13 2014-01-16 Albert Einstein College Of Medicine Of Yeshiva University Aptamer-targeted antigen delivery
US20150226744A1 (en) 2012-09-17 2015-08-13 Ait Austrian Institute Of Technology Gmbh Colon Cancer Diagnostic Method and Means
ES2603589T3 (es) 2012-11-08 2017-02-28 F. Hoffmann-La Roche Ag Ácidos nucleicos que codifican polipéptidos quiméricos para la identificación sistemática de bibliotecas
EP2808392A1 (en) 2013-05-28 2014-12-03 Rheinische Friedrich-Wilhelms-Universität Bonn Aptamers and use of the aptamers in the diagnosis and treatment of cancer
TWI636065B (zh) 2013-08-05 2018-09-21 伊瑪提克斯生物科技有限公司 新穎肽類,細胞及其用於治療多種腫瘤的用途,其製造方法及包含其等之醫藥組成物
CN106661126B (zh) * 2014-05-28 2021-12-10 诺诺公司 TAT-NR2B9c的氯盐
US10317402B2 (en) * 2014-12-03 2019-06-11 Verik Bio, Inc. Identification, selection and use of high curative potential T cell epitopes
GB201507030D0 (en) 2015-04-24 2015-06-10 Immatics Biotechnologies Gmbh Immunotherapy against lung cancers, in particular NSCLC
GB201511546D0 (en) 2015-07-01 2015-08-12 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers

Similar Documents

Publication Publication Date Title
JP2018521641A5 (https=)
JP2018518956A5 (https=)
JP2018536383A5 (https=)
JP2018520653A5 (https=)
JP2018511321A5 (https=)
JP2018518937A5 (https=)
JP2018519243A5 (https=)
JP2019502360A5 (https=)
JP2018529320A5 (https=)
JP2019510465A5 (https=)
JP2021168652A5 (https=)
JP2018510628A5 (https=)
JP2018519825A5 (https=)
CN111868080B (zh) 利用泛等位基因模型进行的新抗原鉴别
JP2018509135A5 (https=)
RU2017137142A (ru) Новые пептиды и комбинации пептидов для применения в иммунотерапии рака легких, в том числе немелкоклеточного рака легких (нмрл) и других видов рака
JP2019506838A5 (https=)
JP2017525336A5 (https=)
AR106920A1 (es) Péptidos y combinaciones de péptidos para el uso en la inmunoterapia contra la leucemia linfocítica crónica (llc) y otros tipos de cáncer
JP5393144B2 (ja) Hla−a*3303拘束性wt1ペプチド、およびそれを含む医薬組成物
US9056069B2 (en) Cancer therapy based on tumor associated antigens derived from cyclin D1
JP2021514178A5 (https=)
JP2020191862A (ja) 上皮性卵巣がんおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ
JP2017502076A5 (https=)
JP2024041841A5 (https=)